Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 113 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Telisotuzumab vedotin for previously treated c-MET overexpressing EGFR wild-type non-squamous non-small cell lung cancer	Telisotuzumab vedotin (ABBV-399;ABBV 399;ABBV399;ABT-399;Teliso-V)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Tepotinib for advanced non-small cell lung cancer harbouring MET exon14- skipping mutations	Tepotinib (MSC-2156119J; TEPMETKO)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Tiragolumab with atezolizumab and pemetrexed and carboplatin or cisplatin for previously untreated advanced non-small-cell lung cancer	Atezolizumab (Tecentriq; MPDL3280A) , Tiragolumab (RG-6058; MTIG7192A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Tiragolumab with atezolizumab for previously untreated non-small cell lung cancer	Atezolizumab (Tecentriq; MPDL3280A) , Tiragolumab (RG-6058; MTIG7192A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2022	View \| Download
Tiragolumab with atezolizumab for treating stage III non-small cell lung cancer after platinum-based chemoradiotherapy	Atezolizumab (Tecentriq; MPDL3280A) , Tiragolumab (RG-6058; MTIG7192A)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Tislelizumab for advanced non-small cell lung cancer after platinum based chemotherapy	Tislelizumab (BGB-A317; BGBA-317)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Tislelizumab with chemotherapy for previously untreated advanced squamous or non-squamous non-small-cell lung cancer	Tislelizumab (BGB-A317; BGBA-317)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Tislelizumab with etoposide and carboplatin or cisplatin for treating small-cell lung cancer	Carboplatin (Paraplatin) , Cisplatin (Platinol) , Etoposide , Tislelizumab (BGB-A317; BGBA-317)	Small-cell lung cancer (SCLC)	Lung and Respiratory Cancer	2022	View \| Download
Trastuzumab deruxtecan for HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer – second line	Trastuzumab deruxtecan (DS-8201a; Enhertu)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Trastuzumab deruxtecan for treating previously untreated locally advanced or metastatic non-small cell lung cancer with HER2 mutations	Trastuzumab deruxtecan (DS-8201a; Enhertu)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2024	View \| Download